Could OMass become the UK's 'big biotech' company?

UK-based OMass Therapeutics' ambition to join the 'big biotech' ranks has been bolstered by an impressive $310m third-round financing.

OMass attracts $420m Roche wager on IBD programme

UK biotech OMass has revealed its first major pharma partnership, with Roche paying $20m upfront for an inflammatory bowel disease programme.

Google, Sanofi back UK biotech OMass' $100m second round

OMass Therapeutics has raised an impressive $100 million in a Series B financing that is said to be the largest ever for a UK biotech focusing on small-molecule drug development.

UK biotech OMass raises £27.5m for GPCR drug discovery